Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study on the Effect of Adjuvant Anti-recurrence Treatment With Rapamycin on Early-stage HCC With Overexpression of ASPH After Radical Surgery.

NCT02724332 is registered in ClinicalTrials.gov with Eastern Hepatobiliary Surgery Hospital as lead sponsor.

NCT NCT02724332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02724332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study on the Effect of Adjuvant Anti-recurrence Treatment With Rapamycin on Early-stage HCC With Overexpression of ASPH After Radical Surgery.
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2012
Completion date
December 31, 2015
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, rapamycin